Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19459110 | 0.83 | SLC6A4 (0.42) | PARP1OPRK1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL4106374 | 0.81 | SLC6A3 (0.40) | CYP2D6PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL18812549 | 0.77 | OPRM1 (0.46) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4296257 | 0.76 | OPRM1 (0.44) | CYP2D6PARP1OPRM1OPRD1GRIN1 | |
| SCHEMBL8218700 | 0.75 | CYP2D6 (0.47) | CYP2D6PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL26206626 | 0.73 | CYP2D6 (0.42) | CYP2D6PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL29185211 | 0.73 | HSD11B1 (0.41) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL8552014 | 0.72 | GRIN2D (0.48) | CYP2D6OPRM1OPRD1GRIN1GRIN2A | |
| SCHEMBL16474300 | 0.71 | OPRM1 (0.44) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL665626 | 0.70 | PARP1 (0.60) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-10011604-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2018-05-10 | — | — | US | disclosed |
| US-9795611-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796723-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796723-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CYP2D6 2024/4885PARP1 1825/4885OPRM1 4080/4885 |
| US-10011604-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | COL2A1, COL1A1, IFNAR1 | CYP2D6 1257/4885PARP1 3377/4885OPRM1 218/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | CYP2D6 2875/4885PARP1 732/4885OPRM1 3096/4885 |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CYP2D6 1095/4885PARP1 1153/4885OPRM1 916/4885 |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | CYP2D6 1095/4885PARP1 1153/4885OPRM1 916/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | CYP2D6 2634/4885PARP1 1570/4885OPRM1 2018/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CYP2D6 2006/4885PARP1 1311/4885OPRM1 2806/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | CYP2D6 983/4885PARP1 2641/4885OPRM1 2369/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | CYP2D6 1155/4885PARP1 1250/4885OPRM1 1739/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CYP2D6 2833/4885PARP1 890/4885OPRM1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.